🔖
Cite This Article
TEKİN, F., DANIŞ, N. (2022). Early combined immunosupression for the management of Crohn's disease. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 4, 112–113. https://ajindex.com/articles/606226
Journals / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 4
Early combined immunosupression for the management of Crohn's disease
- Pages
- 112–113
- Publication Date
- 2022-11-05
- DOI
- —
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗References (1)
- G D'Haens, F Baert, G van Assche, et al. Early combined immuno- suppression or conventional management in patients with new- ly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7. [CrossRef] JF Colombel, WJ Sandborn, W Reinisch, et al. Infliximab, azathio- prine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95. [CrossRef] Khanna R, Bressler B, Levesque BG, et al. Early combined immunosup- pression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015; 386: 1825-34. [CrossRef] Singh S, EV Loftus. Crohn's disease: REACT to save the gut. Lancet 2015; 386: 1800-2. [CrossRef] Immunosuppression for management of Crohn's disease. HH Her- farth, MD Long, MD Kappelman. Lancet 2016; 387: 747-8. [CrossRef] 402 Turk J Gastroenterol 2016; 27: 401-2 Gas